EdgeNewswire

GridAI Technologies (NASDAQ: GRDX) Positions Itself at the Operating Layer of a Continuously Managed Electric Grid

January 14, 2026, 11:34 AM ET

GridAI Technologies (NASDAQ: GRDX) Positions Itself at the Operating Layer of a Continuously Managed Electric Grid
Share to:

GridAI Technologies (NASDAQ: GRDX) is aligning its platform with a structural shift in how the electric grid is operated as accelerating AI workloads, electrification, and distributed energy resources push grid management away from long-range planning and toward continuous, real-time operation. As demand volatility increases and the margin for error narrows, grid intelligence is moving from a periodic optimization function […]

GridAI Technologies (NASDAQ: GRDX) is aligning its platform with a structural shift in how the electric grid is operated as accelerating AI workloads, electrification, and distributed energy resources push grid management away from long-range planning and toward continuous, real-time operation. As demand volatility increases and the margin for error narrows, grid intelligence is moving from a periodic optimization function to an always-on control layer, where software-driven coordination and automation are required to manage live conditions at scale. GridAI’s approach reflects this reality, positioning the company not as a planning tool, but as an operational layer designed to support ongoing orchestration of demand, storage, and generation in a grid that must now be managed continuously rather than intermittently.

To view the full press release, visit https://ibn.fm/v7M9i

About GridAI Technologies Corp.

GridAI Technologies Corp is a publicly listed company on the Nasdaq. The Company is a diversified technology and life sciences company advancing opportunities at the intersection of artificial intelligence and energy infrastructure following its acquisition of Grid AI, Inc. In addition to its GridAI operations, the Company (formerly Entero Therapeutics Inc.) continues to advance its late clinical-stage biopharmaceutical program focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to GRDX are available in the company’s newsroom at https://ibn.fm/GRDX

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Share to:
EdgeNewswire

EdgeNewswire distributes your news to a targeted and established network of journalists and media outlets. We help build visibility and credibility for your organization and brand through trusted media coverage.

Copyright © 2024 - 2025   EdgeNewswire – Cutting Edge Press Release Distribution Services. All Rights Reserved.